APRINOIA Therapeutics, a clinical-stage biotechnology company focused on developing novel drugs for brain health, filed a registration statement with the SEC on Jan. 25 to raise approximately $50 million in an initial public offering. The Cambridge, Massachusetts-based company, which has applied to list its shares on the Nasdaq, is advised by Cooley partners Will Cai and Tim Pitrelli and Maples and Calder. The underwriters, led by US Tiger Securities, are represented by Winston & Strawn partner Michael Blankenship.
Biotech & Pharmaceuticals
January 29, 2024, 11:34 AM